New York, NY, September 13th, 2023 (TopGun Press)
Below are some of the most topical Healthcare Stocks on the BWI Shareholder Confidence Index based on our daily chats with global investors. Below is a link to the Investor Conviction Intel on AstraZeneca.
Pharmaceuticals – AstraZeneca: The obesity names remain topical amongst investors but investors are talking more about AstraZeneca as an individual stock in 3Q. Although the trial update in early July for datopotamab deruxtecan, one of AstraZeneca’s major new drug opportunities being jointly developed with Japan’s Daiichi Sankyo, was not as good as investors had hoped, core ownership remained relatively sticky. However, investor ratings of Strategy, Long & Short Term Growth Potential, CEO and the Momentum of Investor Confidence have declined somewhat thus far in 3Q in part because of it. AstraZeneca’s CEO, Pascal Soriot, garners the most confidence from investors in the Global Pharmaceuticals space by a significant margin, which presents an obvious key man risk according to investors (CLICK HERE FOR THE INVESTOR CONVICTION INTEL ON ASTRAZENECA). The reader will also note the gap between investor ratings of AstraZeneca’s CEO and their ratings of AstraZeneca’s CFO and Senior Management (Bench).
Biotech – Biogen: Investor ratings of Biogen’s Strategy and Board increased thus far in 3Q and since Chris Viehbacher took over as CEO in late 2022, investors now assign confidence ratings to Biogen’s CEO more closely in line with the average of the sector and peer group rather than below. However, this has not translated into more stable investor ownership commitment yet.
Healthcare Services – IQVIA Holdings Inc: New to the BWI Shareholder Confidence Index this quarter, thus far IQVIA is debuting on most Shareholder Confidence metrics at a mid to high second quartile level aside from the Management, Board and Reporting & Disclosure metrics. Investor ratings of those metrics are a little more polarizing.
Medical Technology – Medtronic: Investors have alternating emotions with Medtronic. It is a name that at times can really gain momentum with investors but it is a stormy relationship. Currently investors are focused on perceived mis-executions and Medtronic’s challenges in hitting guidance. Investor ratings of Strategy, Long Term Growth Potential, CFO and Price Appreciation Potential declined thus far in 3Q. Investors rate Medtronic below the sector and peer group benchmarks on most Shareholder Confidence Metrics.
Largest Index Score Increases (Quarter over Quarter) (3Q2023 at Sept 8 vs. 2Q2023):
Viatris Inc +18%
Vertex Pharmaceuticals Inc. +10%
Fresenius SE +8%
GoodRx Holdings Inc +8%
Sanofi +7%
Align Technology Inc. +7%
Brendan Wood International (BWI) serves a dual clientele of world leading investors and their corporate investment targets as well as broker dealers who provide research, sales and trading services to the investment community. Big cap companies looking for comprehensive investor confidence data on their organizations are likely to discover that Brendan Wood partners consult with their investors non stop year round. Investors depend on BWI to quantify the demand side of the investment industry across 1400 names worldwide, including the name by name research sales and trading professionals who influence investor demand.
About Brendan Wood International:
Brendan Wood International (BWI), formed in 1970, is a private advisory group which originates performance investigation programs in the capital markets. Brendan Wood Partners debrief large institutional investors worldwide on a daily basis. There are 2000 investors in the investor panel collectively managing + $50 trillion invested in the 1400 companies on the BWI Index. Relying on its real time performance intelligence, BWI advises public companies, institutional and activist investors, investment banks and broker dealers on strategy, performance and recruitment of TopGun talent. The firm’s partners have formally presented at 1000+ C level strategy meetings and corporate off sites in fifty cities. Brendan Wood founded the exclusive TopGun Club, a performance based institution.
Disclaimer:
We wish to emphasize that all reports, evaluations and assessments contained herein, represent Brendan Wood International’s subjective judgment and opinions, based on our years of experience and on information obtained by us in the course of our research. Much of the factual information contained in the reports has been obtained by us from third parties on whose responses we have relied in good faith, independent verification by Brendan Wood International being, under the circumstances, impossible. While we believe that you will find our reports to be an invaluable tool in formulating your own strategies and judgments, the foregoing should be borne in mind. This report is not meant as investment advice and should not be interpreted as advising on the value of a company’s securities, the advisability of investing in, purchasing or selling any company’s securities or any other conclusion relating to investment/divestiture of a company’s securities. Finally, this report is not intended as an offer or solicitation for the purchase or sale of any company’s securities.
Contacts:
Amanda Knott
Managing Director
Brendan Wood International
+1 416 924 8110
aknott@brendanwood.com
Jordan Novak
Partner
Brendan Wood International
+1 416 924 8110
jnovak@brendanwood.com
Posted in Press Releases
|
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.
